Shopping Cart
- Remove All
- Your shopping cart is currently empty
LASSBio-2052, a derivative of N-acylhydrazone with antitumor activity against hepatocellular carcinoma (HCC), inhibits HCC cells HepG2 and Hep3B with IC50 values of 18 and 41 μM, respectively. LASSBio-2052 arrests the cell cycle at G2/M phase through downregulation of FOXM1 and induces apoptosis in HCC cells [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | LASSBio-2052, a derivative of N-acylhydrazone with antitumor activity against hepatocellular carcinoma (HCC), inhibits HCC cells HepG2 and Hep3B with IC50 values of 18 and 41 μM, respectively. LASSBio-2052 arrests the cell cycle at G2/M phase through downregulation of FOXM1 and induces apoptosis in HCC cells [1]. |
Molecular Weight | 443.42 |
Formula | C23H20F3N3O3 |
Cas No. | 2549160-15-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.